Liposarcoma, well differentiated
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We examined whether MDM2 and/or CDK4 cause WDLPS/DDLPS, using two types of transformed human bone marrow stem cells (BMSCs), 2H and 5H, with five oncogenic hits (overexpression of hTERT, TP53 degradation, RB inactivation, c-MYC stabilization, and overexpression of HRAS<sup>v12</sup>).
|
31160689 |
2019 |
Liposarcoma, well differentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
Combination therapy with CDK4 and RTK inhibitors may be an effective therapeutic option for WDLPS/DDLPS patients with RTK gene amplification.
|
28099935 |
2017 |
Liposarcoma, well differentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
MDM2 and CDK4 were never coexpressed and FISH for MDM2 amplification was consistently negative, highlighting critical biological differences from atypical lipomatous tumor/dedifferentiated liposarcoma.
|
27879515 |
2017 |
Liposarcoma, well differentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry.
|
27597521 |
2017 |
Liposarcoma, well differentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate foci resembling well-differentiated liposarcoma in MPT for MDM2 and CDK4 amplification.
|
26542423 |
2016 |
Liposarcoma, well differentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
Despite indistinguishable morphology all cases of malignant PT with WDLS-like liposarcomatous differentiation were negative for MDM2 and CDK4 IHC and FISH, supporting different underlying pathogenesis.
|
26843318 |
2016 |
Liposarcoma, well differentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
Lipoblastoma (LB) is a rare benign adipocytic tumor of childhood occasionally showing histological similarities to myxoid liposarcoma (ML) or well-differentiated liposarcoma (WDL). p16 immunohistochemistry has proved to be useful in distinguishing various types of liposarcomas, in particular WDL from lipoma, with higher sensitivity and specificity than MDM2 and CDK4 immunohistochemistry.
|
26514741 |
2016 |
Liposarcoma, well differentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
Four cases of atypical lipomatous tumor/well-differentiated liposarcoma (4/26, 15%) with a low MDM2 and CDK4 amplification level (MDM2-CDK4/CEP12 ratio ranging between 2 and 2.5) detected by FISH showed no amplification by MLPA, although gain of MDM2 and CDK4 (ratios ranging between 1.6 and 1.9) was seen with MLPA.
|
25679065 |
2015 |
Liposarcoma, well differentiated
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Histologically, both CDK4 (P=0.007) and JUN (P=0.005) amplifications were associated with dedifferentiated liposarcoma, whereas amplification of the proximal parts of HMGA2 (5'-untranslated region (UTR) and exons 1-3) was associated with atypical lipomatous tumor/well-differentiated liposarcoma (P=0.01).
|
26336885 |
2015 |
Liposarcoma, well differentiated
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recently, a number of tumor-specific chromosome translocations and associated fusion genes have been identified in adipocytic tumors and atypical lipomatous tumors/well-differentiated liposarcomas (ALT/WDL), which have a supernumerary ring and/or giant chromosome marker with amplified sequences of the MDM2 and CDK4 genes.
|
24965044 |
2014 |
Liposarcoma, well differentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
CDK4 amplification predicts recurrence of well-differentiated liposarcoma of the abdomen.
|
25121597 |
2014 |
Liposarcoma, well differentiated
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to assess the prognostic significance of level of CDK4 amplification in MDM2-amplified WDLS/DDLS.
|
23852861 |
2014 |
Liposarcoma, well differentiated
|
0.600 |
Biomarker
|
disease |
CTD_human |
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.
|
23569312 |
2013 |
Liposarcoma, well differentiated
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.
|
23569312 |
2013 |
Liposarcoma, well differentiated
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition to classical morphology of atypical lipomatous tumor with evidence of lipoblasts and atypical adipocytes, immunohistochemistry with nuclear murine double-minute type 2 protein and cyclin-dependent kinase-4 expression as well as fluorescence in situ hybridization analysis showing an amplification of murine double-minute type 2 protein and cyclin-dependent kinase-4 were helpful to establish the diagnosis.
|
21358383 |
2011 |
Liposarcoma, well differentiated
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.
|
20601955 |
2010 |
Liposarcoma, well differentiated
|
0.600 |
Biomarker
|
disease |
CTD_human |
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.
|
20601955 |
2010 |
Liposarcoma, well differentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
An amplification of the MDM2 and CDK4 genes respectively in the atypical lipomatous tumor/well-differentiated liposarcoma areas was detected by fluorescence in situ hybridization (FISH) analysis, and translocations of the CHOP and FUS genes were detected by FISH analysis in the myxoid/round cell liposarcoma areas.
|
18551309 |
2008 |
Liposarcoma, well differentiated
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Studies of cell cycle controlling proteins that interact with CDK4 and MDM2 revealed an abnormally strong expression of cyclins D1 and E. The selective high-level amplification of the 5'-part of HMGA2, including the DNA-binding domains, suggests that this gene is a major target of amplifications in WDLS.
|
18160213 |
2008 |
Liposarcoma, well differentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
Atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDL) and dedifferentiated liposarcoma (DDL) are reported to have murine double-minute type 2 (MDM2) and cyclin-dependent kinase 4 (CDK4) amplification as a characteristic genetic alteration.
|
16938516 |
2006 |
Liposarcoma, well differentiated
|
0.600 |
Biomarker
|
disease |
BEFREE |
Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas.
|
14694526 |
2004 |
Liposarcoma, well differentiated
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The expression of MDM2/CDK4 gene product in the differential diagnosis of well differentiated liposarcoma and large deep-seated lipoma.
|
10755400 |
2000 |
Liposarcoma, well differentiated
|
0.600 |
ChromosomalRearrangement
|
disease |
ORPHANET |
|
|
|